Financial Contrast: Elevance Health (NYSE:ELV) vs. biote (NASDAQ:BTMD)

biote (NASDAQ:BTMD – Get Free Report) and Elevance Health (NYSE:ELV – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Profitability

This table compares biote and Elevance Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
biote -1.08% -8.61% 4.61%
Elevance Health 2.55% 14.97% 5.31%

Volatility and Risk

biote has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Elevance Health has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Institutional and Insider Ownership

21.7% of biote shares are owned by institutional investors. Comparatively, 89.2% of Elevance Health shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 0.3% of Elevance Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares biote and Elevance Health”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
biote $192.22 million 0.18 $27.05 million ($0.10) -9.60
Elevance Health $199.12 billion 0.48 $5.66 billion $23.45 19.02

Elevance Health has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than Elevance Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for biote and Elevance Health, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
biote 1 1 1 1 2.50
Elevance Health 0 7 15 0 2.68

biote currently has a consensus target price of $2.50, suggesting a potential upside of 160.34%. Elevance Health has a consensus target price of $456.48, suggesting a potential upside of 2.33%. Given biote’s higher possible upside, equities research analysts plainly believe biote is more favorable than Elevance Health.

Summary

Elevance Health beats biote on 11 of the 15 factors compared between the two stocks.

About biote

(Get Free Report)

Biote is a medical technology and services company focused on hormone optimization. It supports healthcare providers who offer bioidentical hormone replacement therapy (BHRT), including pellet-based treatment programs for eligible patients. The company’s services include provider training and education, patient and practice support, and hormone testing and treatment protocols. Biote also offers nutritional supplements and related wellness products through participating providers. Biote was founded in 2012 and serves a network of healthcare providers in the United States.

About Elevance Health

(Get Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.